XTRAC Again Receives Significant Exposure at the American Society for Laser Medicine and Surgery Conference in Atlanta.

Business Editors/Health & Medical Writers

American Society for Laser Medicine and Surgery Conference

RADNOR, Pa.--(BW HealthWire)--April 18, 2002

XTRAC(TM) Practitioner Receives Award for Scalp Psoriasis

Presentation; and PhotoMedex Announces date of First

Quarter 2002 Investor Conference Call.

PhotoMedex, Inc. (Nasdaq:PHMD) today provided information on the results of the Company's participation at the 22nd annual meeting of the American Society of Laser Medicine and Surgery (ASLMS) held in Atlanta, April 10-14, 2002.

The ASLMS is the world's preeminent resource for laser research, education, technology and clinical knowledge. The annual meeting is well attended by its membership and in addition to company product demonstrations, hosts internationally renowned speakers and key luminaries giving workshops probing, important and perplexing medical issues.

The XTRAC(TM) was part of an interview by CNN with David J. Goldberg, MD, a leading XTRAC(TM) practitioner. In addition, it was an integral part of six (6) featured presentations including:

-- Repigmentation of Striae (Stretch Marks) with a 308nm Excimer

Laser: David J. Goldberg, MD, Skin Laser and Surgery

Specialists of New York and New Jersey and Director of Laser

Research in the Department of Dermatology at New York's Mount

Sinai School of Medicine reported on his pioneering efforts

using the XTRAC(TM) on Striae, more commonly known as stretch

marks. Dr. Goldberg, both in his in-studio CNN interview and

again with CBS-Atlanta, which covered the PhotoMedex product

booth, commented, "the excimer laser targets the pigment cells

in the white scar and causes them to produce more pigment,

thereby improving the quality of the scar's color." He further

commented, "The results of our study look very promising and I

expect to submit the study for publication after the ASLMS

meeting. Stretch marks are one of the biggest cosmetic

concerns I hear among women, but overweight men are also

susceptible."

Dr. Goldberg's research follows the progress of 10 subjects

treated for stretch marks at weekly intervals over a five week

period. The results show the treatments re-pigment stretch

marks, making them less noticeable. Stretch marks commonly

occur from pregnancy and substantial weight gain when the skin

is stretched beyond its elastic limits and actually thins out.

This thinned out skin initially appears red from inflammation,

but eventually turns white, leaving a mature stretch scar.

-- Managing Complications of Laser Skin Resurfacing: The lecture focused on
specific advanced techniques for photodamaged and scarred skin using the latest
laser systems available. The prestigious course instructors included Richard E.
Fitzpatrick, MD, Roy G. Geronemus, MD and David J. Goldberg, MD.

-- Successful Treatment of Vitiligo with 308nm Excimer Laser: James M. Spencer,
MD and Suhail Hadi, MD.

-- Treatment of Facial Hypopigmentation and Hypopigmented scars with use of the
308nm Excimer Laser: Richard E. Fitzpatrick, MD.

-- 308nm Excimer Laser Repigmentation of Scars and Striae M.
Alexiandes-Armenkakas, MD, Paul Friedman, MD, Erick Mafong, MD, Roy Geronemus,
MD.

-- Nursing Role in the use of 308nm Excimer Laser System for Psoriasis and
Pigmented Disorders: Patti Owens, James Brazil, MD,

Jeff O'Donnell, President and CEO, commented, "we are overwhelmed and pleased by the extensive medical community endorsement of XTRAC(TM) laser therapy and their pioneering efforts to uncover new applications for this platform technology. Clinical evidence continues to accumulate, supporting our strategy to see the XTRAC(TM) as an indispensable tool in the dermatology suite. Broad based reimbursement in the upcoming months will complete the circle whereby patients suffering with inflammatory skin disorders will also make this therapy the treatment of choice."

Photomedicine Society Award

The company further announced that Samir Gupta, MD, a Clinical Fellow in Lasers and Photomedicine, Department of Dermatology, Harvard Medical School was named the recipient of the prestigious "Photomedicine Society Award" for his presentation at the recent 11th Annual Meeting of the Photomedicine Society on Thursday, February 21, 2002, in New Orleans. His presentation on the "308 nm Excimer Laser for the Treatment of Scalp Psoriasis" discussed his very positive experience in utilizing the XTRAC(TM) laser for this prevalent and very difficult to treat medical condition. Dr. Gupta reported that he found the XTRAC(TM) device to be user friendly and that most patients had significant improvement in their scalp psoriasis in 6 treatments on average with the potential to clear in 10 treatments. He also noted that the patients experienced minimal side effects and had a high degree of patient satisfaction.

Conference Call

PhotoMedex will hold a conference call to discuss the Company's first quarter 2002 results on Thursday, May 2, at 4:30 p.m. Eastern Standard Time.

The first quarter results will be announced on May 2 prior to the conference call.

To participate in the conference call, dial 1-800-967-7140 approximately 5 to 10 minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from Thursday, May 2 at 7:30 p.m. EST until midnight on Thursday, May 9, by dialing 1-888-203-1112 and using confirmation code # 734510.

The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the call at those sites.

About PhotoMedex:

PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA approval to market the XTRAC(TM) laser system for the treatment of psoriasis, vitiligo, and eczema.

The Company's excimer laser system generating 308-nm UV-B radiation is the first FDA-approved laser treatment for psoriasis, which is the second most common skin disorder in the U.S. The National Psoriasis Foundation estimates that psoriasis afflicts more than 7 million Americans and that between 150,000 and 260,000 new cases are diagnosed each year. The XTRAC(TM) laser system is also the first FDA approved excimer laser system to treat vitiligo, a skin disease that, according to the National Vitiligo Foundation, afflicts approximately 1 to 2% of Americans, and eczema, a skin disease that is estimated to afflict 15 million Americans.

Some paragraphs of this press release, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1993, as amended and Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its expected financial return from operations. Factors such as these could have an adverse effect on PhotoMedex' results of operations. In light of significant uncertainties inherent in forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by PhotoMedex and its subsidiaries that it will be achieved The XTRAC laser system has not yet been approved for the application of Repigmentation.